142 related articles for article (PubMed ID: 9542684)
1. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
[TBL] [Abstract][Full Text] [Related]
3. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
Vardi Y; Lidgi S; Moskovitz B; Levin RD
Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
[TBL] [Abstract][Full Text] [Related]
4. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
Asuar Aydillo S
Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
[No Abstract] [Full Text] [Related]
5. Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction.
Purvis K; Egdetveit I; Christiansen E
Int J Impot Res; 1999 Oct; 11(5):287-99. PubMed ID: 10553808
[TBL] [Abstract][Full Text] [Related]
6. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
[TBL] [Abstract][Full Text] [Related]
7. Experience with triple-drug therapy in a pharmacological erection program.
Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
[TBL] [Abstract][Full Text] [Related]
8. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
Valdevenito R; Melman A
Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
Lee LM; Stevenson RW; Szasz G
J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
[TBL] [Abstract][Full Text] [Related]
11. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
Floth A; Schramek P
J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
[TBL] [Abstract][Full Text] [Related]
12. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
von Heyden B; Donatucci CF; Kaula N; Lue TF
J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
[TBL] [Abstract][Full Text] [Related]
13. An improved vasoactive drug combination for a pharmacological erection program.
Bennett AH; Carpenter AJ; Barada JH
J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
[TBL] [Abstract][Full Text] [Related]
15. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
[TBL] [Abstract][Full Text] [Related]
16. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
Purvis K; Brekke I; Christiansen E
Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
[TBL] [Abstract][Full Text] [Related]
18. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
19. [Intracavernous pharmacotherapy for organic impotence in the elderly].
Richter S; Shalev M; Nissenkorn I
Harefuah; 1990 Aug; 119(3-4):66-7. PubMed ID: 2227669
[TBL] [Abstract][Full Text] [Related]
20. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
